Acrivon Therapeutics, Inc.ACRV
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing precision oncology therapies based on its proprietary ACRIVALID platform, which identifies and validates drug targets and biomarkers. The company's lead candidate, ACR-368, is in Phase 2 trials for ovarian and endometrial cancers, and its pipeline includes additional programs targeting CDK2 and other cell-cycle regulators. Investors track ACRV for its platform-driven approach to improving clinical trial success rates and its potential in biomarker-selected patient populations.
Congressional Interest in Acrivon Therapeutics, Inc. (ACRV)
No congressional trades have been disclosed for Acrivon Therapeutics, Inc. (ACRV) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading ACRV?
No congressional trades found for this stock.